AU · rank #1 · 2026-09-11
SNT
GPW · PLN · $770M (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.279 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$2.35 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $373.00 | +10.9% |
| Momentum acceleration 3-month minus 12-month momentum. | +2.55% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | — |
| Gross margin TTM | +23.5% |
| 52w high | $398.40 |
| Market cap (USD) | $770M |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Synektik is a Polish nuclear medicine and diagnostic imaging group combining equipment distribution with radiopharmaceutical supply and recurring service contracts, generating ~334M PLN in trailing recurring revenue growing 52% YoY.
Rationale
All three covering analysts revised EPS upward in the last 30 days with 100% revision agreement and a mean Buy rating (2.0), while Q3 FY2025/26 revenue nearly doubled YoY, giving the analyst-upside signal concrete fundamental backing rather than mere sentiment drift.
Material risks
- 1Analyst count of only 3 with 25.7% target price dispersion means the 10.9% consensus upside is fragile — a single model revision or missed tender award could collapse the signal entirely.
- 2Synektik's equipment distribution revenue is exposed to Polish public healthcare capex cycles and competitive pressure from global OEM imaging vendors, which could compress the hardware margin (gross margin already modest at 23.5%) if procurement budgets tighten post-2026 investment surge.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.